The intracellular and plasma concentrations of HIV protease inhibitors (HPIs) vary widely in vivo. It is unclear whether there is a concentration-dependent effect of HPIs such that at increasing concentration they may either block their own efflux (leading to 'autoboosting') or influx (leading to saturability/decreased intracellular accumulation). Conclusions: There are complex and variable drug-specific rather than class-specific effects of the HPIs on their own accumulation.
Introduction
Highly active antiretroviral therapy (HAART) has markedly decreased the morbidity and mortality of HIV-infected individuals. However, despite the improvements associated with HAART, the virus continues to evolve in cellular reservoirs and anatomical sanctuary sites during therapy even when below detectable levels of HIV are achieved in plasma. The causes of persistent HIV infection despite undetectable plasma levels remain incompletely understood but probably include multiple factors such as persistence of virus in cellular reservoirs (e.g. CD4+ T cells and cells of the macrophage lineage) and anatomical sanctuary sites (brain and possibly testis), 1 -7 pharmacological and poor compliance. Collectively these sites represent a major impediment to the eradication of HIV. Viral sanctuary sites may result from the overexpression, in sites of HIV replication, of membrane-bound drug efflux transporters, e.g. P-glycoprotein (P-gp; ABCB1), multidrug resistanceassociated proteins (MRPs; ABCCs) and breast cancer resistance protein (BCRP; ABCG2).
Some studies have provided evidence that HIV protease inhibitors (HPIs), e.g. saquinavir, ritonavir, lopinavir, atazanavir and darunavir, may be reduced by these drug efflux transporters, 8 -15 which may potentially promote the emergence of mutant viruses. Recent studies by others and us have also shown that organic anion transporting polypeptides (OATPs) may also influence the intracellular accumulation of some HPIs. 16, 17 HPIs exhibit complex interactions with drug transporters, drug metabolizing enzymes (CYPs) and serum proteins. These complex interactions lend support for the discrepancy between the intracellular concentrations of the HPIs measured in vivo and in vitro/ex vivo. 18 Although data on association between genetic polymorphisms in drug metabolizing enzymes and transporter proteins are equivocal, they may explain, in part, the variable and complex plasma and cellular concentrations and treatment outcomes of HIV-infected patients. For example, despite some of the HPIs, e.g. lopinavir, being a substrate for ABCB1 and ABCC, 12, 19 an earlier retrospective study of HIV-infected patients under antiretroviral therapy found no influence of the ABCB1 C3435T polymorphism on the plasma and peripheral blood mononuclear cell (PBMC) levels of lopinavir (or the non-nucleoside reverse transcriptase inhibitor, efavirenz) 20, 21 even though polymorphisms at the ABCB1 C3435T and G2677T/ A, MRP1 (ABCC1) C218T and G2168A and MRP2 (ABCC2) G1249A have been associated with alterations in ABCB1, ABCC1 and ABCC2 activity. 22 -26 However, some studies found no association between the concentrations of saquinavir (alone or when boosted with ritonavir), atazanavir or lopinavir and polymorphisms in ABCB1 C3435T and G2677T/A. 27, 28 Furthermore, recent studies on three common exonic ABCB1 polymorphisms, C1236T, G2677T/A and C3435T, showed that these are poor predictors of the concentrations of lopinavir and ritonavir in saliva, semen and plasma. 29 However, there is evidence of some association between G4544A polymorphism in ABCC2 and higher accumulation of lopinavir in PBMCs of HIV-treated patients. 21 Similar studies on 74 HIV-infected patients showed significantly higher plasma levels of atazanavir in patients with genotype CC than those with CT or TT for polymorphism at the ABCB1 C3435T. 30 Studies in cultured cells showed that the permeability of amprenavir, indinavir, lopinavir and ritonavir was greater in ABCB1 (G1199A) cells than in ABCB1 wt cells, suggesting that ABCB1 G1199A polymorphism may impact on the systemic bioavailability of HPIs. 12 Clearly if inter-individual differences in the bioavailability of HPIs is caused by genetic variants of ABCB1, ABCC1 and ABCC2, this may have a profound effect on the pharmacokinetics and pharmacodynamics of substrate drugs.
Inhibition of first-pass metabolism of the HPIs by cytochrome P450 (CYP) enzymes markedly increases the bioavailability of most HPIs and hence their therapeutic efficacy. Thus, ritonavirboosted HPIs have become part of the standard of care for HIV-infected patients. 31 -38 Data on the interaction of HPIs are equivocal: we recently showed that amprenavir and atazanavir increased the intracellular accumulation of lopinavir in both cultured and primary human cells, suggesting a potential role of inhibiting ABCC and ABCB1 in boosting the intracellular concentration of some HPIs. 19 Furthermore, combinations of HPIs with more potent efflux inhibitors have been shown to increase the brain penetration of HPIs. 39 -42 However, some combinations of HPIs may not efficiently increase their organ (e.g., brain) permeability. 43 -45 These complex interactions are accentuated as some HPIs are also known to up-regulate ABCB1, ABCC and CYP expression and function. 46 -51 Thus, optimum HIV treatment requires careful consideration of these parameters to avoid therapy-limiting drug-drug, drug-transporter and drug-enzyme interactions, and some important data necessary to fully understand the intracellular pharmacology of HPIs are still missing.
Inadequate plasma or intracellular concentrations of antiretrovirals may lead to treatment failure. In order to adequately manage this, dose modification, guided by therapeutic drug monitoring of plasma concentration, is sometimes used as a strategy to address this problem. As HAART involves the concomitant use of multiple drugs, it appears important to evaluate the concentration-dependent effects of these drugs on intracellular accumulation and this was the aim of the present study. 
Materials and methods

Reagents
Cell culture
The parental cell line was CEM (a CD4 T cell line). CEM VBL (VBL, P-gp overexpressing) cells were selected using vinblastine. CEM E1000 (E1000, MRP1 overexpressing) cells were selected with epirubicin. Cell volume (range 0.8-1 pL) and cell density were measured using a CASY Cell Counter (Sedna Scientific Ltd, Dronfield, Derbyshire, UK). We have previously validated the expression of the transporters in our laboratory. 10 The cells were maintained at 378C and 5% CO 2 in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS).
Isolation of PBMCs
PBMCs were isolated from blood buffy coats using Lymphoprep, following the manufacturer's instructions. Cell volume (0.3 -0.4 pL) and cell density were measured using a CASY Cell Counter.
Ethics
No ethical approval was required in the collection and use of the blood products from the blood transfusion services. step, the samples were incubated in 1.5 mL Eppendorf stubs for a further 15-20 min before the assay was terminated, samples processed and analysed as described previously. 13 Briefly, after incubating the cells for 10-15 min at 378C in a water bath, the samples were then centrifuged at 15000 g for 1 min at 48C. Then a 100 mL aliquot of the medium was taken from each sample for scintillation counting and the pellets were washed three times in ice-cold phosphate-buffered saline (PBS) before solubilization of the pellets in 100 mL of distilled water for radioactivity counting. Data from the radioactivity counts were expressed as cellular accumulation ratio (CAR), being the ratio of the amount of labelled HPI associated with the cell pellets to the amount in a similar volume of medium after incubation. The cell volumes for CEM and its variant cells and PBMCs ranged from 0.3 to 0.4 pL and 0.8 to 1 pL, respectively.
Effects of various concentrations of unlabelled
In order to investigate the mechanism of self-stimulation we also evaluated the effects of adding the radiolabelled HPIs before the unlabelled HPIs (termed co-incubation). Here we pre-incubated the cells with 0.5 mM [ 14 C]lopinavir in RPMI medium supplemented with 10% FCS for 5 min, followed by a further incubation with various concentrations (0-30 mM) of unlabelled lopinavir for 5 min, before the samples were finally incubated for 15 min and later processed as described above. To further characterize the effects of lopinavir on transporter activity, we evaluated the accumulation of [ Effects of tariquidar, MK571 and frusemide (alone and in combination with unlabelled lopinavir) on the accumulation of [ 14 
C]lopinavir
As inhibitors of drug efflux transporters such as tariquidar (inhibits ABCB1/ABCG2 54 -56 ), MK571 (inhibits ABCC 10,17,57 -59 ) and frusemide (inhibits ABCC1/2 13 ) increased the intracellular accumulation of HPIs, 13, 19 these agents were employed in the current studies, at the indicated concentrations, to characterize HPI-mediated activity against the cells. Here, CEM and its variant cells were initially pre-treated for 5 min with 1 mM tariquidar (CEM and CEM VBL cells) or 50 mM MK571 (CEM and CEM E1000 cells) to inhibit ABCB1 and ABCC, respectively. Thereafter, the cells were incubated without or with 10 mM unlabelled lopinavir. In separate experiments, PBMCs were pre-treated for 5 min without or with 1 mM tariquidar or 50 mM frusemide (previously shown to increase the accumulation of lopinavir in PBMCs 19 ), followed by a further incubation treatment of the cells in the absence or presence of 10 and 30 mM lopinavir for 5 min. Thereafter, 0.5 mM [ 14 C]lopinavir in RPMI medium supplemented with 10% FCS was added and the samples incubated for 15 min before the assay samples were processed as described above.
Data and statistical analyses
Results are expressed as CAR, being the ratio of the amount of labelled HPI associated with the cell pellets to the amount in a similar volume of medium after incubation. Data from all of the experiments were expressed as mean+SD. The Shapiro-Wilk test was used to assess the distribution of the data, followed by the Kruskal-Wallis test to allow multiple comparisons of drug-treated samples with respective controls. Analyses were performed using Statsdirect statistical software version 2.3.1, 2003 (StatsDirect Ltd, Altrincham, Cheshire, UK). In each case, significance between control and drug-treated means was assumed if P, 0.05.
Results
Unlabelled lopinavir increased the accumulation of [ Janneh et al.
cycling of an exchange transporter is accelerated by outgoing pre-loaded unlabelled substrate, thus boosting the uptake of radiolabelled compound added later. To investigate the mechanism of self-stimulation we examined the effect of adding the radiolabel before the unlabelled compound. Pre-incubation of cells with [ 14 C]lopinavir followed by various concentrations of unlabelled lopinavir also significantly (P,0.001) increased the CAR of [ 14 C]lopinavir in a concentration-dependent manner, suggesting that the mechanism is an inhibition of efflux transporters rather than true trans-acceleration (Figure 1b) . We also observed that in PBMCs there was a significant increase (P,0.001) in the CAR of 14 C]lopinavir was significantly increased in cells treated with 1 mM tariquidar (P,0.001) or 50 mM MK571 (P,0.01) in combination with 10 mM unlabelled lopinavir, the observed increase was identical to that measured in samples treated with 10 mM unlabelled lopinavir alone (Figure 3a) . Overall, co-incubation of MK571 or tariquidar with unlabelled lopinavir (at 10 mM) did not enhance the accumulation of [ 14 C]lopinavir over that observed with unlabelled lopinavir alone.
In the PBMCs, the effects of fixed concentrations (10 and 30 mM) of lopinavir were investigated alone and in combination with 1 mM tariquidar or 50 mM frusemide (Figure 3b ). Tariquidar and frusemide also significantly (P, (Figure 3b) .
To further understand lopinavir-mediated increase in its own accumulation, we investigated its effects on other known substrates of ABCB1 and ABCC. To this end we evaluated the effects of various concentrations (0 -30 mM) of unlabelled lopinavir on the accumulation of [ Ritonavir increased the accumulation of [ 
Discussion
Given the wide variability in plasma concentrations of HPIs achieved with standard dosing, it is important to understand how the variable plasma concentration impacts on intracellular drug accumulation. This is because being efficient inhibitors, substrates and inducers of some drug efflux proteins and drug metabolizing enzymes, 9,46,47,51 -53,60 -65 there is a complex interaction between HPIs and drug efflux/influx transporters and enzymes, especially if the patients are on other medications. 66 -69 Indeed alterations in ABCB1 and ABCC2 activity have been associated with single nucleotide polymorphisms in ABCB1 (C3435T and G2677T/A), ABCC1 and ABCC2 (G1249A). 22 -26 While some studies showed no association between the exposure of HPIs and polymorphisms in ABCB1 C3435T, C1236T and G2677T/A, 27 -29 some in vitro and in vivo studies found some association between G4544A and G1199A polymorphisms in ABCC2 and ABCB1, respectively and higher accumulation of some HPIs, 12, 21, 30 suggesting that these polymorphisms may impact on the systemic bioavailability of various HPIs that are substrates of ABCB1 and ABCC2.
Clearly, the effect of modifying extracellular drug concentrations on intracellular accumulation requires careful consideration. Here we demonstrate that unlabelled lopinavir pharmaco-enhances its own accumulation in both cultured and primary human cells. The 'self-enhancement' measured in CEM, CEM E1000 (ABCC1 overexpressing) and CEM VBL (ABCB1 overexpressing) (Figure 1 ) suggests that lopinavir inhibits various efflux proteins, possibly including ABCB1 and ABCC1. However, since the effects are quite similar in CEM and CEM E1000 it is possible that MRP1 is only minimally affected and that other efflux transporters might be involved. Given that PBMCs express ABCB1, ABCG2, ABCC1 and ABCC2, 13, 19 'the self-enhancement' of the accumulation of [ 14 C]lopinavir by unlabelled lopinavir in these cells (Figure 2 ) also suggests inhibition of one or more of these efflux proteins. However, there is also evidence that HPIs inhibit ABCG2, but are not substrates of this protein. 52 If lopinavir is an inhibitor of ABCB1 and ABCC1 activity, how does its inhibitory profile compare with relatively specific inhibitors of these proteins (e.g. tariquidar and MK571)? To address this question, we compared (i) the inhibitory profiles of unlabelled lopinavir alone with those of tariquidar and MK571 and (ii) the inhibitory effects of unlabelled lopinavir (alone and in combination with tariquidar or MK571). As shown previously, 19 we observed that tariquidar and MK571 significantly increased the CAR of [ 14 C]lopinavir in cell lines and primary cells. However, the increase in the CAR of [ 14 C]lopinavir by unlabelled lopinavir alone was markedly higher than that measured for tariquidar-or MK571-treated samples alone (Figure 3a) . This is consistent with unlabelled lopinavir having a greater effect at increasing its own accumulation in cells overexpressing ABCB1 and ABCC than tariquidar and MK571, respectively, although this needs to be tested over a wider range of inhibitor concentrations.
Inhibition of efflux proteins leads to an increase in the intracellular accumulation of lopinavir. 17, 19, 70 Here the CAR of However, a similar profile of inhibition to that observed in CEM and its variant cells was measured when PBMCs were pre-treated with tariquidar or frusemide in the presence of unlabelled lopinavir (Figure 3a versus b) . The observed effects of lopinavir on its own accumulation are consistent with inhibition of ABCB1 and ABCC activity, and supports previous observations that HPIs inhibit drug transporters. 19, 53 Indeed, the observation that unlabelled lopinavir increased the CAR of [ 3 H]saquinavir and [ 3 H]ritonavir in CEM, CEM E1000 (ABCC1 overexpressing) and CEM VBL (ABCB1 overexpressing) cells (Figure 3c and d) provides additional evidence that the observed effects are mediated via ABCB1 and ABCC inhibition.
To extend these observations, we evaluated the effects of unlabelled ritonavir, saquinavir and atazanavir on the accumulation of [ (Figure 4a ). Although cells pre-treated with tariquidar, followed by the addition of unlabelled ritonavir (at 30 mM) to the bathing medium showed a significantly increased CAR of [ H]ritonavir. However, combination of unlabelled ritonavir (at 10 mM) with frusemide abrogated the increase in CAR of [ 3 H]ritonavir previously measured with frusemide alone. This is possibly due to saturation of intracellular binding sites by high concentrations of unlabelled ritonavir such that inhibition of ABCC is unable to increase the intracellular concentration of radiolabelled ritonavir high enough to displace the unlabelled compound. We provide evidence for differential accumulation of atazanavir in the cultured cells and in PBMCs (Figure 6 ), supporting previous studies that atazanavir is a substrate of ABCB1 48 
